Barclays highlighted several stocks in its research coverage that it rates underweight and that it says could see significant losses ahead.
Related Posts
The weekend tariff news was ‘unequivocally positive’ for stocks, Fundstrat’s Tom Lee says
The rollback is a sign that President Donald Trump is listening to business leaders about their concerns with the tariffs, Lee said.
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
How to build up your bets – and your returns – in dividend-paying stocks
Your brokerage firm has a tool that allows you to build positions in dividend payers over time, a move that could boost returns.